Applied DNA Sciences (APDN) Competitors

Applied DNA Sciences (NASDAQ:APDN) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap industrials companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.

Does the MarketBeat Community favor APDN or BIAF?

Applied DNA Sciences received 292 more outperform votes than bioAffinity Technologies when rated by MarketBeat users. Likewise, 57.91% of users gave Applied DNA Sciences an outperform vote while only 50.00% of users gave bioAffinity Technologies an outperform vote.

Company	Underperform	Outperform
Applied DNA Sciences	Outperform Votes 293 57.91%	Underperform Votes 213 42.09%
bioAffinity Technologies	Outperform Votes 1 50.00%	Underperform Votes 1 50.00%

Does the media favor APDN or BIAF?

In the previous week, Applied DNA Sciences and Applied DNA Sciences both had 1 articles in the media. bioAffinity Technologies' average media sentiment score of 0.00 beat Applied DNA Sciences' score of -1.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied DNA Sciences	Negative
bioAffinity Technologies	Neutral

Which has more volatility and risk, APDN or BIAF?

Applied DNA Sciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500.

Do analysts rate APDN or BIAF?

Applied DNA Sciences currently has a consensus target price of $75.00, indicating a potential upside of 12,462.81%. bioAffinity Technologies has a consensus target price of $6.00, indicating a potential upside of 1,954.09%. Given Applied DNA Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Applied DNA Sciences is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied DNA Sciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
bioAffinity Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is APDN or BIAF more profitable?

bioAffinity Technologies has a net margin of -91.22% compared to Applied DNA Sciences' net margin of -228.12%. Applied DNA Sciences' return on equity of -101.57% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied DNA Sciences	-228.12%	-101.57%	-62.43%
bioAffinity Technologies	-91.22%	-205.09%	-115.95%

Do insiders & institutionals have more ownership in APDN or BIAF?

22.2% of Applied DNA Sciences shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 0.0% of Applied DNA Sciences shares are held by company insiders. Comparatively, 35.1% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has better valuation & earnings, APDN or BIAF?

Applied DNA Sciences has higher earnings, but lower revenue than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Applied DNA Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied DNA Sciences	$3.74M	0.18	-$6.99M	-$35.85	-0.02
bioAffinity Technologies	$9.36M	0.57	-$7.94M	-$0.72	-0.41

Summary

Applied DNA Sciences beats bioAffinity Technologies on 10 of the 17 factors compared between the two stocks.